Business Context and Reporting Period
The supplied filing is Nanophase Technologies Corporation’s unaudited Form 10-Q for the quarter ended September 30, 2015; it does not identify Solesence, Inc. Nanophase develops and manufactures engineered nano- and sub-micron materials for personal care, coatings, polishing, energy, and other applications. Unless noted otherwise, financial amounts below are in thousands of dollars.
Financial Performance and Position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Net revenue | $2,786 | $2,654 | $8,033 | $8,116 |
| Gross profit | $883 | $796 | $2,440 | $2,535 |
| Gross margin | 31.7% | 30.0% | 30.4% | 31.2% |
| Operating loss | $(151) | $(348) | $(845) | $(846) |
| Net loss | $(155) | $(349) | $(854) | $(849) |
| Net loss per share | $(0.01) | $(0.01) | $(0.03) | $(0.03) |
- For the first nine months, operating cash outflow was $542, versus $890 in 2014; investing outflow was $236, and financing provided $165. Cash declined $613 from year-end 2014 to $1,249.
- At September 30, current assets were $3,621 and current liabilities $1,574. Short-term debt was $200, and capital lease obligations totaled $195. The $200 line-of-credit draw was repaid October 2.
- Accounts receivable rose to $1,478 from $388 at year-end 2014, while net inventory declined to $643 from $950. Stockholders’ equity was $3,158, down from $3,846.
Changes Versus Prior Period
- Third-quarter revenue rose 5% year over year, with higher orders from the largest personal-care/sunscreen customer and an additional medical-diagnostics order. Nine-month revenue declined 1%.
- Nine-month sales to the largest customer were nearly $1 million below the prior-year period; increased polishing and coatings sales partly offset the decline.
- Q3 gross margin improved, but nine-month gross profit and margin fell. Management attributed production-cost pressure partly to customer order volatility and manufacturing inefficiencies.
- Q3 and nine-month selling, general and administrative expense declined year over year; research and development expense was also lower for the nine-month period.
Outlook, Risks, and Other Matters
- Management expected fourth-quarter sales to the largest customer to exceed fourth-quarter 2014, and believed operating cash, cash and unused credit would fund plans through 2015. Expected remaining-2015 capital spending was $10–$30. These are management expectations, not a guarantee.
- Management expected a slight increase in R&D expense and a modest increase in SG&A for the remainder of 2015. It noted that margins depend on revenue volume and mix, cost reductions, and the ability to pass through raw-material price increases.
- Customer concentration is substantial: the top three customers accounted for 69%, 6%, and 9% of Q3 revenue. BASF, the largest customer, has supply-agreement provisions that may permit technology licensing and equipment transfer if specified triggers occur, including trailing-period losses alongside cash and certain investments below $1 million. Cash at quarter-end was approximately $1.2 million, including the temporary $200 line draw.
- The working-capital line provided up to $300, subject to eligible receivables and other conditions, required at least $1 million of cash including borrowings, and was due to expire March 4, 2016. Additional financing might not be available on acceptable terms; insufficient capital could curtail plans and raise going-concern concerns.
- Other risks include reliance on key customers, uncertain adoption of products, manufacturing capacity constraints, commodity input costs, competition, and potential dilution from future financing. The company reported no material pending legal proceedings and said disclosure controls were effective.
Important Facts for Investors to Verify
- Confirm the issuer: the provided filing is for Nanophase Technologies Corporation, not Solesence, Inc.
- Track cash, operating cash burn, receivables, and availability under the working-capital line, including the post-quarter repayment of the $200 draw.
- Monitor BASF sales concentration and compliance with supply-agreement financial and other covenants.
- Assess whether new polishing, coatings, energy, and other applications can offset weaker sales to the largest customer and support improved margins.
- Compare management’s stated 2015 sales, spending, and liquidity expectations with subsequent results; the filing cautions that interim results are not necessarily indicative of full-year performance.